ToolGen Incorporated’s exclusive CRISPR license agreement with Bayer has expired without renewal. The company, listed as KR:199800, no longer holds the rights previously granted for CRISPR-related technologies under the partnership.
ToolGen challenges Vertex and Lonza over patent rights for the CRISPR-based therapy **Casgevy** in Europe, despite setbacks at the European Patent Office (EPO). The dispute centers on intellectual property claims related to genome-editing technology. ToolGen continues legal action to defend its position in the market.
ToolGen has filed a complaint against Vertex Pharmaceuticals over its gene therapy **Casgevy®**. The dispute centers on alleged patent infringement and intellectual property conflicts related to the therapy’s development. ToolGen claims its proprietary CRISPR-based technology was used without proper authorization, raising concerns over biotech industry collaboration practices.
ToolGen secures a U.S. patent for its CRISPR-Cas9 RNP platform technology, expanding its intellectual property in the world’s largest biotech market. The platform improves editing efficiency and accuracy, reinforcing ToolGen’s global patent portfolio. The company also files a U.S. lawsuit against Vertex Pharmaceuticals and CRISPR Therapeutics, alleging infringement of its foundational CRISPR technology used in CASGEVY, an FDA-approved gene-editing therapy.
ToolGen, Inc. sues Vertex Pharmaceuticals, Lonza, and RoslinCT in the UK over alleged patent infringement related to Vertex’s genome editing therapy **CASGEVY**. The lawsuit targets manufacturing and commercialization activities tied to the therapy’s development. ToolGen claims its intellectual property rights are violated by Vertex’s processes.